Identification Of Circulating Long Noncoding Rna Linc00152 As A Novel Biomarker For Diagnosis And Monitoring Of Non-Small-Cell Lung Cancer

Nandi Li,Xiao Bo Feng,Qian Tan,Ping Luo,Wei Jing,Man Zhu,Chunzi Liang,Yong Ning,Jiancheng Tu

DOI: https://doi.org/10.1155/2017/7439698

2017-01-01

Disease Markers

Abstract:Objective. Long noncoding RNAs (lncRNAs) have been reported to play vital roles in non-small-cell lung cancer (NSCLC). Recently, long noncoding RNA Linc00152 has been reported to play important roles in various cancers. In this study, our aim was to investigate its expression pattern and clinical significance and further evaluate its diagnostic value for NSCLC. Methods. The levels of Linc00152 were detected in NSCLC tissues and plasma samples by quantitative real-time PCR (qRT-PCR). Receiver operating characteristic (ROC) curves were depicted to evaluate the diagnostic value. Results. We found that Linc00152 levels were upregulated in both NSCLC tissues and plasma samples. Plasma Linc00152 levels were significantly lower in postoperative samples than in preoperative samples. Besides, high Linc00152 expression was significantly correlated with tumor size (r = 0.293, P = 0.005) and tumor stage (r = 0.324, P = 0.011). The ROC curves indicated that plasma Linc00152 has high diagnostic accuracy for NSCLC, and the area under curve (AUC) for NSCLC versus healthy was 0.816 (95% CI: 0.757-0.875). Moreover, we found that the combination of Linc00152 and CEA could provide a more powerful diagnosis efficiency than Linc00152 or CEA alone (AUC = 0.881, 95% Cl: 0.836 0.926). Conclusions. Plasma Linc00152 could serve as a promising biomarker for diagnosing and monitoring NSCLC.